Comparative Pharmacology
Head-to-head clinical analysis: ETHRANE versus KETALAR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ETHRANE versus KETALAR.
ETHRANE vs KETALAR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Enflurane is a volatile inhalational anesthetic that potentiates GABA-A receptor activity and inhibits excitatory neurotransmission, resulting in general anesthesia.
Noncompetitive NMDA receptor antagonist; inhibits glutamate activity, modulates opioid receptors, and interacts with other neurotransmitter systems.
1-5% inspired concentration via inhalation, titrated to effect for maintenance of general anesthesia.
1-4.5 mg/kg IV or 6.5-13 mg/kg IM for induction of anesthesia; 0.1-0.5 mg/kg/min IV infusion for maintenance.
None Documented
None Documented
Context-sensitive half-life: approximately 2-5 minutes after short procedures; prolonged after prolonged administration due to slow washout from fat stores.
Terminal elimination half-life: 2.5-3 hours (ketamine); norketamine: 12 hours. Clinical context: Short half-life facilitates rapid recovery, but context-sensitive half-life increases with infusion duration.
Primarily exhaled unchanged via lungs (>95%); less than 5% metabolized in liver to fluoride ion and other metabolites, with renal excretion of metabolites.
Renal: 90% as metabolites (norketamine, dehydronorketamine); unchanged: 2-4%. Fecal: <3%.
Category C
Category C
General Anesthetic
General Anesthetic